Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

NCT00143871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Non-Hodgkin's

Interventions

DRUG: Rituximab

Sponsor

University of Michigan Rogel Cancer Center